Medical Manufacturing Technologies Acquired by Perimeter Solutions (~13.7x EBITDA)
- Will Hamilton
- Dec 13, 2025
- 2 min read
On December 12 2025, Perimeter Solutions, Inc. (NYSE: PRM) entered into a definitive agreement to acquire Medical Manufacturing Technologies (MMT) from Arcline Investment Management for approximately $685 million in cash. MMT is a leading provider of highly engineered machinery, aftermarket consumables and services for the manufacturing of minimally invasive medical devices. The transaction positions Perimeter to diversify its offerings beyond its core fire‑safety and specialty chemical businesses into the medical device manufacturing market, complementing its existing portfolio with MMT’s precision engineering capabilities and recurring aftermarket revenue streams. MMT’s global footprint, spanning 14 production facilities and serving over 1,000 medical device OEMs and CDMOs, enhances Perimeter’s channel breadth into interventional cardiology, neurovascular and other minimally invasive device segments, while supporting increased scale and cross‑sell opportunities.
Medical Devices EBITDA Multiples
MMT is projected to generate roughly $140 million in revenue and $50 million in adjusted EBITDA for the full year 2025, implying multiples of 4.9x revenue and 13.7x EBITDA.
Medical Devices M&A Deal Volume
The number of announced medical devices and supplies deals increased in 2025 after several years of a mostly declining trend. Volume averaged 55 quarter up from 48 per quarter in 2024, but still down from 64 per quarter in 2023, 57 in 2022 and 70 in 2021. Looking at the individual segments, the relatively small CDMO / OEM / components sub-segment rebounded strongly after a significant decline in 2024 disrupted a strong growth trend.
Other Medical Devices Deals
Read Scope Research's take on other medical device transactions:
About Scope Research
The Scope Research Healthcare M&A Valuation Database currently has financial details related to 321 medical devices, equipment and supplies deals, segmented by type, including 156 deals with disclosed EBITDA multiples. The data can be purchased individually, while our affordable annual subscriptions provide access to all of our healthcare M&A databases and segments, updated continuously.
Don't hesitate to reach out to Will Hamilton at will@scoperesearch.co with questions about your specific situation.